相似文献
1
Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.
Trends Pharmacol Sci. 2016 Nov;37(11):933-944. doi: 10.1016/j.tips.2016.09.001. Epub 2016 Sep 28.
2
SSRI Augmentation by 5-Hydroxytryptophan Slow Release: Mouse Pharmacodynamic Proof of Concept.
Neuropsychopharmacology. 2016 Aug;41(9):2324-34. doi: 10.1038/npp.2016.35. Epub 2016 Mar 2.
3
Slow-release delivery enhances the pharmacological properties of oral 5-hydroxytryptophan: mouse proof-of-concept.
Neuropsychopharmacology. 2019 Nov;44(12):2082-2090. doi: 10.1038/s41386-019-0400-1. Epub 2019 Apr 29.
4
Restoration of 3,4-methylenedioxymethamphetamine-induced 5-HT depletion by the administration of L-5-hydroxytryptophan.
Neuroscience. 2007 Aug 10;148(1):212-20. doi: 10.1016/j.neuroscience.2007.05.024. Epub 2007 Jul 12.
5
Effects of Serotonin and Slow-Release 5-Hydroxytryptophan on Gastrointestinal Motility in a Mouse Model of Depression.
Gastroenterology. 2019 Aug;157(2):507-521.e4. doi: 10.1053/j.gastro.2019.04.022. Epub 2019 May 7.
6
Effects of oral 5-hydroxytryptophan on a standardized planning task: insight into possible dopamine/serotonin interactions in the forebrain.
Hum Psychopharmacol. 2013 May;28(3):270-3. doi: 10.1002/hup.2314. Epub 2013 Apr 22.
7
The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse.
Psychopharmacology (Berl). 2014 Dec;231(23):4527-40. doi: 10.1007/s00213-014-3595-1. Epub 2014 May 9.
8
Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice.
Psychopharmacology (Berl). 2008 Dec;201(2):203-18. doi: 10.1007/s00213-008-1268-7. Epub 2008 Aug 19.
9
Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa.
J Psychopharmacol. 2008 Jun;22(4):426-33. doi: 10.1177/0269881107082025. Epub 2008 Feb 28.
10
Selectivity of (3)H-MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural effects.
Br J Pharmacol. 2004 Mar;141(6):1015-23. doi: 10.1038/sj.bjp.0705693. Epub 2004 Mar 1.
引用本文的文献
1
The Pathogenesis and Medical Treatment of Depression: Opportunity and Challenge.
Neurol Int. 2025 Aug 4;17(8):120. doi: 10.3390/neurolint17080120.
2
5-Hydroxytryptophan artificial synaptic vesicles across the blood-brain barrier for the rapid-acting treatment of depressive disorder.
Mater Today Bio. 2024 Nov 22;29:101357. doi: 10.1016/j.mtbio.2024.101357. eCollection 2024 Dec.
3
The role of tryptophan derivatives as anti-kinetoplastid agents.
Heliyon. 2023 Dec 15;10(1):e23895. doi: 10.1016/j.heliyon.2023.e23895. eCollection 2024 Jan 15.
4
The differential sensitivity of the hypothalamic-hypophysial-ovarian axis to 5-hydroxytryptophan alters the secretion of estradiol.
Exp Physiol. 2024 Mar;109(3):365-379. doi: 10.1113/EP091158. Epub 2023 Dec 8.
5
Notifications and Health Consequences of Unauthorized Pharmaceuticals in Food Supplements.
Pharmacy (Basel). 2023 Sep 23;11(5):154. doi: 10.3390/pharmacy11050154.
6
Interactions Between Antidepressants and Intestinal Microbiota.
Neurotherapeutics. 2023 Mar;20(2):359-371. doi: 10.1007/s13311-023-01362-8. Epub 2023 Mar 7.
7
Lactobacillus rhamnosus GG normalizes gut dysmotility induced by environmental pollutants via affecting serotonin level in zebrafish larvae.
World J Microbiol Biotechnol. 2022 Sep 14;38(12):222. doi: 10.1007/s11274-022-03409-y.
8
L-5-hydroxytryptophan promotes antitumor immunity by inhibiting PD-L1 inducible expression.
J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2021-003957.
9
Persimmon leaf extract alleviates chronic social defeat stress-induced depressive-like behaviors by preventing dendritic spine loss via inhibition of serotonin reuptake in mice.
Chin Med. 2022 Jun 6;17(1):65. doi: 10.1186/s13020-022-00609-4.
10
Edible Mushrooms as a Potential Component of Dietary Interventions for Major Depressive Disorder.
Foods. 2022 May 20;11(10):1489. doi: 10.3390/foods11101489.
本文引用的文献
1
SSRI Augmentation by 5-Hydroxytryptophan Slow Release: Mouse Pharmacodynamic Proof of Concept.
Neuropsychopharmacology. 2016 Aug;41(9):2324-34. doi: 10.1038/npp.2016.35. Epub 2016 Mar 2.
2
A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies.
Neuropsychopharmacology. 2016 Jun;41(7):1803-12. doi: 10.1038/npp.2015.348. Epub 2015 Nov 20.
3
Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
Curr Med Res Opin. 2015 Jun;31(6):1179-89. doi: 10.1185/03007995.2015.1037732. Epub 2015 May 6.
4
Adjunctive treatment with asenapine augments the escitalopram-induced effects on monoaminergic outflow and glutamatergic neurotransmission in the medial prefrontal cortex of the rat.
Int J Neuropsychopharmacol. 2014 Oct 31;18(3):pyu068. doi: 10.1093/ijnp/pyu068.
5
The murine serotonin syndrome - evaluation of responses to 5-HT-enhancing drugs in NMRI mice.
Behav Brain Res. 2015 Jan 15;277:204-10. doi: 10.1016/j.bbr.2014.04.033. Epub 2014 Apr 27.
6
Serotonin syndrome.
BMJ. 2014 Feb 19;348:g1626. doi: 10.1136/bmj.g1626.
7
Innovative solutions to novel drug development in mental health.
Neurosci Biobehav Rev. 2013 Dec;37(10 Pt 1):2438-44. doi: 10.1016/j.neubiorev.2013.03.022. Epub 2013 Apr 3.
8
Serotonin and beyond: therapeutics for major depression.
Philos Trans R Soc Lond B Biol Sci. 2013 Feb 25;368(1615):20120536. doi: 10.1098/rstb.2012.0536. Print 2013.
9
L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials.
Am J Psychiatry. 2012 Dec;169(12):1267-74. doi: 10.1176/appi.ajp.2012.11071114.
10
The 5-HT deficiency theory of depression: perspectives from a naturalistic 5-HT deficiency model, the tryptophan hydroxylase 2Arg439His knockin mouse.
Philos Trans R Soc Lond B Biol Sci. 2012 Sep 5;367(1601):2444-59. doi: 10.1098/rstb.2012.0109.
Zotero 插件